Dyne Therapeutics, Inc. entered an underwriting agreement with Morgan Stanley & Co. LLC and Jefferies LLC to sell 18.3 million shares of common stock, with up to 2.745 million additional shares available for purchase by underwriters.
Dyne Therapeutics, Inc. entered an underwriting agreement with Morgan Stanley & Co. LLC and Jefferies LLC to sell 18.3 million shares of common stock, with up to 2.745 million additional shares available for purchase by underwriters.